S&P Futures
3,756.75 -32.75 (-0.86%) Dow Futures
30,516.00 -265.00 (-0.86%) Nasdaq Futures
11,423.50 -106.00 (-0.92%) Russell 2000 Futures
1,686.50 -21.50 (-1.26%) Crude Oil
105.46 -0.30 (-0.28%) Gold
1,801.50 -5.80 (-0.32%)
Natera, Inc. (NTRA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 36.87 |
| Open | 36.31 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 800 |
| Day's Range | 34.84 - 37.14 |
| 52 Week Range | 26.10 - 129.09 |
| Volume | |
| Avg. Volume | 1,510,967 |
| Market Cap | 3.413B |
| Beta (5Y Monthly) | 1.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.89 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 85.20 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NTRA
Related Research
- Natera, Inc.Analyst Report: Illumina IncIllumina Inc., based in San Diego, provides sequencing and array-based solutions for genetic analysis. The company's products and services are sold to genomic research centers, academic institutions, government and commercial laboratories, and hospitals, as well as to pharmaceutical, biotech, agrigenomics, and consumer genomics businesses. The company's portfolio of products and services are designed to accelerate and simplify genetic analysis. The company also invests in startup companies that are pursuing promising genomic-related opportunities. It has roughly 9,100 full-time employees. ILMN shares are included in the S&P 500 index.RatingFair ValueEconomic Moat15 hours agoArgus Research
- PR Newswire
Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of a manuscript in a leading journal in the organ transplant space, Transplantation, validating the performance of a novel two-threshold algorithm for its Prospera™ test for the assessment of transplant rejection. Prospera incorporates the donor fraction and the estimated amount of donor-derived cfDNA (dd-cfDNA) when assessing active rejection. In the study, Natera's new method demonstr
- Simply Wall St.
Insiders rewarded with a US$942k addition on top of their US$5.0m purchase as Natera, Inc. (NASDAQ:NTRA) hits US$3.7b
Natera, Inc. ( NASDAQ:NTRA ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
- PR Newswire
Natera Showcases Leadership in Transplantation at ATC 2022 with New Data on its Prospera and Renasight Tests
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has presented data on the clinical utility of the company's Prospera™ and Renasight™ tests in 14 sessions at the American Transplant Congress (ATC) 2022 meeting. This expands on the thirteen peer-reviewed papers that have been published over the last twelve months, demonstrating the strong performance of both assays.
